Brief: EMA's CHMP Recommends Extension Of Therapeutic Indication For Pandemic Influenza Vaccine H5N1 AstraZeneca
16/10/2026 11:12
BRIEF-EMA's CHMP Recommends Extension Of Therapeutic Indication For Pandemic Influenza Vaccine H5N1 AstraZeneca Oct 16 (Reuters) - EMA's CHMP:
EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR PANDEMIC INFLUENZA VACCINE H5N1 ASTRAZENECA
EMA'S CHMP: RECOMMENDS EXTENSION OF THERAPEUTIC INDICATION FOR KYINSU
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AstraZeneca
See all newsAstraZeneca says FDA approves drug for rare kidney disease in adults
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Early US flu season, current strain may signal risk for younger people; doctors urge shots
AstraZeneca partners with Oracle for AI-driven clinical trials
Factbox: Pharma sector doubles down on AI to slash costs, timelines